오스코텍
Not investment advice · For research purposes only; not a solicitation or an offer of any financial product. Past statistics do not indicate future outcomes. Facts from filings and public sources; not investment advice. No valuation estimate, direction or trading levels are provided.
① Fact table
Values as filed · consolidated / separate basis per year · no interpretation
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | Unit |
|---|---|---|---|---|---|---|
| 매출액 | 3,902,734,752 | 5,062,376,493 | 4,950,929,999 | 34,007,602,680 | 99,838,669,222 | KRW |
| 영업이익 | -28,096,765,516 | -28,638,371,344 | -32,655,289,595 | -2,733,857,885 | 52,081,332,705 | KRW |
| 당기순이익 | -26,262,552,170 | -24,429,544,991 | -24,279,525,966 | 876,526,893 | 52,343,085,512 | KRW |
| 자본총계 | 28,827,564,416 | 122,508,361,959 | 98,918,425,620 | 127,755,760,649 | 181,307,409,042 | KRW |
| 부채총계 | 17,778,798,890 | 21,914,692,257 | 37,860,914,026 | 38,418,568,371 | 43,005,621,434 | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준)· in house | 61.67 | 17.89 | 38.27 | 30.07 | 23.72 | % |
| Statement basis | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated |
Source: dart_fnltt · Computed in house · card as of 2026-10-13 · Filing date per year: not on the card (see the filing timeline below) · 'in house' marks items computed from the values above
② Profitability breakdown
Arithmetic on the fact table only · same year, same basis · '—' where a value is missing or the denominator is 0 or below · in each panel the bar height maps the span from the most negative to the largest positive value onto the panel height · no interpretation attached
Source: computed in house from the fact table · card as of 2026-10-13
③ My own calculation
A simple residual-income formula. You enter the assumptions; only the base equity is filled in from the filing. The result is computed from your assumptions and is not a figure this site publishes.
V = B₀ + (ROE − r) × B₀ ÷ (1 + r − ω)
Fill in all four boxes to compute. The site fills in nothing but the base equity.
Computed in this browser only; nothing you type is sent or stored.
- Base close 2026-10-13
- 35,350
- 80%
- 33,523.26 ~ 37,928.54
- 90%
- 32,951.36 ~ 38,920.02
- Ledger row
- f8cdff4b…
Source: fsc_stock_price · published 2026-10-14T11:05:08+09:00 · No direction implied
No day scored yet — no basis for a hit rate.
- 2026-10-06Filing title as filed주주명부폐쇄기간또는기준일설정 original ↗Source: dart_disclosure
- 2026-10-06Filing title as filed주주총회소집결의 (임시주주총회) original ↗Source: dart_disclosure
- 2026-09-23Filing title as filed소송등의제기ㆍ신청(경영권분쟁소송) original ↗Source: dart_disclosure
- 2026-09-18Filing title as filed[기재정정]주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-09-17Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-09-17Filing title as filed주식등의대량보유상황보고서(약식) original ↗Source: dart_disclosure
- 2026-09-04Filing title as filed투자판단관련주요경영사항(임상시험결과) (알츠하이머 치료 후보물질 ADELY01 임상 1a/1b상 임상시험결과보고서(CSR) 수령) original ↗Source: dart_disclosure
- 2026-09-01Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-08-20Filing title as filed기업설명회(IR)개최 original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed반기보고서 (2026.06) original ↗Source: dart_disclosure
- 2026-07-23Filing title as filed[기재정정]최대주주변경 original ↗Source: dart_disclosure
- 2026-07-23Filing title as filed최대주주변경을수반하는주식담보제공계약체결 original ↗Source: dart_disclosure
- 2026-07-23Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-07-03Filing title as filed기업설명회(IR)개최 original ↗Source: dart_disclosure
- 2026-06-17Filing title as filed[기재정정]투자판단관련주요경영사항 (SYK 저해제 후보물질 세비도플레닙(SKIO703) 기술수출 계약 체결) original ↗Source: dart_disclosure
- 2026-06-01Filing title as filed투자판단관련주요경영사항 (SYK 저해제 후보물질 세비도플레닙(SKIO703) 기술수출 계약 체결) original ↗Source: dart_disclosure
- 2026-05-29Filing title as filed주식등의대량보유상황보고서(약식) original ↗Source: dart_disclosure
- 2026-05-22Filing title as filed투자판단관련주요경영사항(임상시험계획승인신청등결정) (SKIO703의 약물 제형 변경을 위한 임상 1상 IND 승인) original ↗Source: dart_disclosure
- 2026-05-22Filing title as filed주식등의대량보유상황보고서(약식) original ↗Source: dart_disclosure
| Layer | Badge | n | Note |
|---|---|---|---|
| range | unknown | 0 | 80%·90% 범위의 전향 적중 기록(목표일 개장 전 박제 → 종가 공표 뒤 채점) |
| fair_value | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| direction | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| trade_levels | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| Valuation estimate | not provided | — | Not published: no demonstrated discriminative power |
| Direction (up or down) | not provided | — | Not published: no demonstrated discriminative power |
| Trading levels | not provided | — | Not published: no demonstrated discriminative power |
Why this?
Checking…